VIDEO: Transplant eligibility may impact treatment options in multiple myeloma

ByHenry Chi Hang Fung, MD, FACP, FRCPE

ByMarley V. Ghizzone

Fact checked byMindy Valcarcel, MS

CHICAGO — In this video, Henry Chi Hang Fung, MD, FACP, FRCPE, discussed findings assessing the treatment of patients with multiple myeloma who are ineligible for transplant.

Fung, chair and professor in the bone marrow transplant and cellular therapies department at Fox Chase Cancer Center, highlighted two phase 3 studies presented at ASCO Annual Meeting.

He also discussed updates from a trial that looked at a similar treatment plan for patients with multiple myeloma who are transplant eligible.

“For high-risk patients/standard-risk patients, we should consider four drug regimens as the treatment for patients with multiple myeloma transplant eligible and transplant ineligible,” Fund said.”

References:

Facon T, et al. Abstract 7500. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.
Leleu XP, et al. Abstract 7501. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.
Rodriguez-Otero P, et al. Abstract 7502. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Fung reports serving on the speakers’ bureau of AstraZeneca, Incyte and Johnson and Johnson.

Take Homes in Multiple Myeloma

Read more

VIDEO: Transplant eligibility may impact treatment options in multiple myeloma

References:

Related Content